U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. FDA Debarment List (Drug Product Applications)
  5. 08/01/1994
  1. FDA Debarment List (Drug Product Applications)

08/01/1994

[Federal Register: August 1, 1994]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 93N-0349]

Satish R. Shah; Denial of Hearing and Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is denying a hearing for and is issuing a final order under section 306(a)(2) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 335a(a)(2)) permanently debarring Mr. Satish R. Shah, #28858-037, L.S.C.I. Allenwood, P.O. Box 1500, White Deer, PA 17887, from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Shah was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of a drug product and relating to the regulation of a drug product under the act.

EFFECTIVE DATE: August 1, 1994

ADDRESSES: Application for termination of debarment to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Tamar S. Nordenberg, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-2041.

SUPPLEMENTARY INFORMATION:

  1. Background

    Mr. Satish R. Shah, a former research and development supervisor in Par Pharmaceutical, Inc.'s (Par), Research and Development Department, was sentenced on April 30, 1993, for his conviction of, among other counts, one count of making a false statement to a Federal agency, a felony offense under 18 U.S.C. 1001. The basis for this conviction was Mr. Shah's material false statement to FDA regarding the formulation and the bioequivalency and stability testing of Par's generic drug product Triamterene 75 milligram (mg)/Hydrochlorothiazide 50 mg tablets.

    In a certified letter received by Mr. Shah on October 22, 1993, the Deputy Commissioner for Operations offered Mr. Shah an opportunity for a hearing on the agency's proposal to issue an order under section 306(a) of the act permanently debarring Mr. Shah from providing services in any capacity to a person that has an approved or pending drug product application. The proposal was based on a finding, under section 306(a) of the act, that Mr. Shah was convicted of a felony under Federal law for conduct relating to the development, approval, and regulation of a drug product.

    The certified letter informed Mr. Shah that his request for a hearing could not rest upon mere allegations or denials but must present specific facts showing that there was a genuine and substantial issue of fact requiring a hearing. The letter also notified Mr. Shah that if it conclusively appeared from the face of the information and factual analyses in Mr. Shah's request for a hearing that there was no genuine and substantial issue of fact, FDA would enter summary judgment against him, making findings and conclusions, and denying his request for a hearing.

    Mr Shah requested a hearing in a letter dated November 23, 1993. However, Mr. Shah has not submitted any information or analyses to justify a hearing. Mr. Shah's failure to raise any issues of fact, and his failure to submit information or analyses in support of his hearing request, constitute a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment (21 CFR 12.22).

  2. Denial of Hearing

    Because he failed to present any arguments or information to show why he should not be debarred, FDA finds that Mr. Shah has failed to identify any genuine and substantial issue of fact requiring a hearing. Accordingly, pursuant to 21 CFR 12.28, the agency denies Mr. Shah's request for a hearing.

  3. Findings and Order

    Therefore, the Acting Deputy Commissioner for Operations, under section 306(a) of the act and under authority delegated to her (21 CFR 5.20), finds that Mr. Satish R. Shah has been convicted of a felony under Federal law for conduct: (1) Relating to the development or approval, including the process for development or approval, of a drug product (21 U.S.C. 335a(a)(2)(A)); and (2) relating to the regulation of a drug product (21 U.S.C. 335a(a)(2)(B)). Specifically, Mr. Shah's felony conviction under 18 U.S.C. 1001 was for making a false statement to FDA by submitting false pilot batch records for a drug product. Pilot batch records are used by FDA in its determination of whether to approve a generic drug product based, among other things, on bioequivalence with its name brand counterpart. Because a showing of bioequivalence is a prerequisite to drug approval, the actions for which Mr. Shah was convicted affected the drug approval process

    As a result of the foregoing findings, Mr. Satish R. Shah is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 382), or under section 351 of the Public Health Service Act (42 U.S.C. 262), effective (insert date of publication in the Federal Register) (21 U.S.C. 335a(c)(1)(B) and (c)(2)(A)(ii) and 21 U.S.C. 321(ee)). Any person with an approved or pending drug product application who knowingly uses the services of Mr. Shah, in any capacity, during his period of debarment, will be subject to civil money penalties. If Mr. Shah, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties. In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Mr. Shah during his period of debarment.

    Any application by Mr. Shah for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 93N- 0349 and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: July 18, 1994.
Linda A. Suydam,
Interim Deputy Commissioner for Operations.
[FR Doc. 94-31250 Filed 12-20-94; 8:45 am]
BILLING CODE 4160-01-F

Back to Top